This article introduces the requirements for a biosimilar license in Brazil and addresses questions about their quality, safety, and efficacy.
Sílvia Helena Cestari de Oliveira
Advertisement
Sílvia Helena Cestari de Oliveira is researcher in the biotechnology division at Cristália Produtos Químicos Farmacêuticos, Itapira, Brazil.
Articles by Sílvia Helena Cestari de Oliveira
Advertisement
Latest Updated Articles
Brazilian Regulation of Biosimilar Products: What Is Important to KnowSeptember 1st 2022
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
3
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
4
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
5